Astria's Losses Widen Amid R&D Surge, BioCryst Merger Looms

TL;DR

**Astria's burning cash faster with R&D, but the BioCryst merger is a lifeline that could stabilize its future.**

AI Summary

Astria Therapeutics, Inc. reported a net loss of $31.643 million for the three months ended September 30, 2025, an increase from a net loss of $24.534 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss widened to $98.404 million, up from $68.634 million in the prior year. Collaboration revenue was $706,000 for both the three and nine months ended September 30, 2025, with no revenue reported in 2024. Research and development expenses significantly increased to $77.880 million for the nine months ended September 30, 2025, from $56.945 million in 2024, reflecting intensified clinical development for navenibart and STAR-0310. General and administrative expenses also rose to $29.745 million for the nine-month period in 2025, compared to $25.022 million in 2024. The company's cash, cash equivalents, and short-term investments stood at $227.7 million as of September 30, 2025, down from $328.132 million at December 31, 2024, but management estimates this is sufficient for at least twelve months of operations. A significant strategic development is the pending merger with BioCryst Pharmaceuticals, Inc., announced on October 14, 2025, which is expected to impact future financial performance and operational strategy.

Why It Matters

Astria's escalating R&D expenses, up 36.7% year-over-year to $77.880 million, signal aggressive advancement of its lead drug candidates, navenibart and STAR-0310, which is critical for future value creation in the competitive biopharmaceutical landscape. The pending merger with BioCryst Pharmaceuticals, Inc. could significantly alter Astria's competitive position, potentially providing greater resources and market reach for its HAE and AD treatments, impacting investors' long-term returns. For employees, the merger introduces uncertainty but also potential for expanded roles within a larger entity. Customers could benefit from accelerated development and broader access to new therapies if the combined entity achieves its goals, especially for rare diseases like HAE.

Risk Assessment

Risk Level: high — Astria Therapeutics reported an accumulated deficit of $773.2 million as of September 30, 2025, and has not generated any product revenues, indicating a high reliance on financing. Net cash used in operating activities was $102.371 million for the nine months ended September 30, 2025, demonstrating significant cash burn. While the company estimates its $227.7 million in cash, cash equivalents, and short-term investments are sufficient for at least twelve months, the lack of product revenue and substantial operating losses present a high financial risk.

Analyst Insight

Investors should closely monitor the progress and terms of the pending merger with BioCryst Pharmaceuticals, Inc., as it represents a critical strategic pivot. Evaluate the combined entity's pipeline, financial projections, and market positioning to determine if the merger creates sufficient value to offset Astria's current high burn rate and lack of product revenue. Consider the potential for dilution if additional financing is required post-merger.

Financial Highlights

debt To Equity

0.16

revenue

$706K

operating Margin

-157.3%

total Assets

$271.866M

total Debt

$38.613M

net Income

-$98.404M

eps

-$1.70

gross Margin

N/A

cash Position

$227.7M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $98.404M — Net Loss (for the nine months ended September 30, 2025, increased from $68.634M in 2024)
• $77.880M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $56.945M in 2024)
• $706K — Collaboration Revenue (for the nine months ended September 30, 2025, compared to $0 in 2024)
• $773.2M — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• $227.7M — Cash, Cash Equivalents, and Short-term Investments (as of September 30, 2025, providing liquidity for at least 12 months)
• $102.371M — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025, reflecting high cash burn)
• 57,084,838 — Common Shares Outstanding (as of October 31, 2025)
• 36.7% — Increase in R&D Expenses (from $56.945M in 2024 to $77.880M in 2025 for the nine-month period)

Key Players & Entities

• Astria Therapeutics, Inc. (company) — registrant
• BioCryst Pharmaceuticals, Inc. (company) — merger partner
• Jefferies LLC (company) — underwriter for ATM program
• navenibart (drug) — lead product candidate for HAE
• STAR-0310 (drug) — second product candidate for AD
• Hereditary Angioedema (disease) — target indication for navenibart
• Atopic Dermatitis (disease) — target indication for STAR-0310
• Securities and Exchange Commission (regulator) — filing oversight
• $773.2 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $227.7 million (dollar_amount) — cash, cash equivalents, and short-term investments as of September 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Cash Burn [high — financial]: The company reported a net loss of $98.404 million for the nine months ended September 30, 2025, an increase from $68.634 million in the prior year. This significant cash burn, reflected in net cash used in operating activities of $102.371 million, raises concerns about long-term financial sustainability.
• Intensified R&D Spending [medium — operational]: Research and development expenses increased by 36.7% to $77.880 million for the nine months ended September 30, 2025, from $56.945 million in the prior year. While this reflects progress in clinical development for key drug candidates, it also contributes to the widening net loss.
• Declining Cash Reserves [medium — financial]: Cash, cash equivalents, and short-term investments decreased from $328.132 million at December 31, 2024, to $227.7 million as of September 30, 2025. While management estimates this is sufficient for at least twelve months, the burn rate necessitates careful financial management.
• Drug Development and Approval Risks [high — regulatory]: The company's success is heavily dependent on the successful development and regulatory approval of its drug candidates, navenibart and STAR-0310. Delays or failures in clinical trials or regulatory reviews could significantly impact future revenue and financial performance.
• Merger Uncertainty [medium — market]: The pending merger with BioCryst Pharmaceuticals, Inc., announced on October 14, 2025, introduces uncertainty regarding future strategic direction, operational integration, and potential changes in management and R&D priorities.

Industry Context

The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like Astria Therapeutics focus on developing novel therapies for rare diseases, often relying on strategic partnerships and substantial funding to advance their pipelines. The competitive landscape is intense, with many companies vying for breakthroughs in similar therapeutic areas.

Regulatory Implications

Astria's drug development programs are subject to stringent regulatory oversight by agencies like the FDA. Any delays in clinical trials, adverse findings, or failure to meet regulatory standards for navenibart and STAR-0310 could lead to significant setbacks and impact the company's ability to bring its products to market.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress
2. Evaluate the impact of the BioCryst merger
3. Assess cash runway and future financing needs

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $31.643 million for the quarter and $98.404 million for the nine months, with cash reserves at $227.7 million.
• 2024-09-30: End of Q3 2024 — Reported net loss of $24.534 million for the quarter and $68.634 million for the nine months.
• 2025-10-14: Merger with BioCryst Pharmaceuticals announced — This significant strategic event is expected to reshape the company's future operations and financial strategy.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has historically operated at a loss, with an accumulated deficit of $773.198 million as of September 30, 2025.)

Collaboration revenue

Revenue generated from agreements with other companies, often involving joint development or licensing of intellectual property. (Represents a new source of revenue for Astria, totaling $706,000 for the nine months ended September 30, 2025.)

Right-of-use asset

An asset representing a lessee's right to use an underlying asset for the lease term, recognized under ASC 842 lease accounting standards. (Reflects the company's long-term lease obligations, with a value of $4.254 million as of September 30, 2025.)

Deferred revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (The company recognized $4.495 million in current deferred revenue and $12.041 million in non-current deferred revenue as of September 30, 2025, suggesting upfront payments for future services or products.)

Year-Over-Year Comparison

Astria Therapeutics reported a significant increase in net loss for the nine months ended September 30, 2025, to $98.404 million from $68.634 million in the prior year, driven by a substantial rise in R&D expenses to $77.880 million. While collaboration revenue emerged at $706,000, it did not offset the increased operating costs. Cash reserves have decreased from $328.132 million at year-end 2024 to $227.7 million, though management maintains it's sufficient for at least 12 months. New risks related to the pending merger with BioCryst Pharmaceuticals have also been introduced.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ATXS The Nasdaq

Filing Documents

• atxs-20250930x10q.htm (10-Q) — 1608KB
• atxs-20250930xex10d1.htm (EX-10.1) — 560KB
• atxs-20250930xex31d1.htm (EX-31.1) — 11KB
• atxs-20250930xex31d2.htm (EX-31.2) — 11KB
• atxs-20250930xex32d1.htm (EX-32.1) — 9KB
• 0001104659-25-110377.txt ( ) — 7540KB
• atxs-20250930.xsd (EX-101.SCH) — 44KB
• atxs-20250930_cal.xml (EX-101.CAL) — 41KB
• atxs-20250930_def.xml (EX-101.DEF) — 196KB
• atxs-20250930_lab.xml (EX-101.LAB) — 420KB
• atxs-20250930_pre.xml (EX-101.PRE) — 299KB
• atxs-20250930x10q_htm.xml (XML) — 1207KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity for the three months ended March 31, 2025 and 2024, June 30, 2025 and 2024, and September 30, 2025 and 2024 8 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 4.

Controls and Procedures

Controls and Procedures 35

OTHER INFORMATION

PART II. OTHER INFORMATION 36 Item 1A.

Risk Factors

Risk Factors 36 Item 5. Other Information 42 Item 6. Exhibits 43

SIGNATURES

SIGNATURES 44 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance, strategy, future financial condition and clinical and preclinical development programs. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, clinical and preclinical development programs, regulatory filings and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our pending merger with BioCryst Pharmaceuticals, Inc., or BioCryst, including the expected benefits of the merger, our and BioCryst's ability to recognize the benefits of the merger, the anticipated timing of the closing of the merger, the anticipated financial impact of the merger, BioCryst's or the combined company's performance following the merger, including future financial and operating results, anticipated approval and commercialization of navenibart, pharmaceutical research and development, such as drug discovery, preclinical and clinical development activities

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Astria Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 96,280 $ 59,820 Short-term investments 131,441 268,312 Accounts receivable 17,243 — Prepaid expenses and other current assets 8,582 6,511 Total current assets 253,546 334,643 Right-of-use asset 4,254 5,114 Other assets 14,066 2,606 Total assets $ 271,866 $ 342,363 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,137 $ 4,320 Accrued expenses 16,481 13,427 Operating lease liabilities, current 1,404 1,384 Deferred revenue, current 4,495 — Total current liabilities 23,517 19,131 Operating lease liabilities, net of current portion 3,055 3,969 Deferred revenue, net of current portion 12,041 — Total liabilities 38,613 23,100 Commitments (Note 7) Stockholders' equity: Preferred stock, $ 0.001 par value per share, 4,908,620 shares authorized and no shares issued or outstanding — — Series X redeemable convertible preferred stock, $ 0.001 par value per share, 91,380 shares authorized; 31,107 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 95,324 95,324 Common stock, $ 0.001 par value per share, 150,000,000 shares authorized; 56,434,894 and 56,434,219 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 57 57 Additional paid-in capital 911,014 898,513 Accumulated other comprehensive gain 56 163 Accumulated deficit ( 773,198 ) ( 674,794 ) Total stockholders' equity 233,253 319,263 Total liabilities and stockholders' equity $ 271,866 $ 342,363 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents Astria Therapeutics, Inc.

View Full Filing

View this 10-Q filing on SEC EDGAR